Literature DB >> 2525042

Down's syndrome and atherosclerosis.

S Ylä-Herttuala1, J Luoma, T Nikkari, T Kivimäki.   

Abstract

Necropsy findings in patients with Down's syndrome have suggested an absence of atherosclerosis throughout the cardiovascular system, but there are also contradictory results. We compared the left coronary arteries of 15 institutionalised Down's syndrome patients (5 males, 10 females, mean age 51 years) with those of 6 other institutionalised mentally retarded patients (4 males, 2 females, mean age 49) and 20 normal, free-living subjects (10 males, 10 females, mean age 48) by macroscopic inspection of the opened coronary arteries and by biochemical analysis of their intima-media. The arteries of Down patients contained a lower percentage of raised lesions and less calcium than the arteries of the control groups. Thus, even though the coronary arteries of mongoloids were not completely free of atherosclerosis, it was milder than in other mental patients and free-living subjects of the same age.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525042     DOI: 10.1016/0021-9150(89)90110-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  28 in total

1.  Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins.

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

Review 2.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

3.  Down syndrome and microRNAs.

Authors:  Aldina Brás; António S Rodrigues; Bruno Gomes; José Rueff
Journal:  Biomed Rep       Date:  2017-11-17

4.  Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?

Authors:  Troy T Rohn; Katie L McCarty; Julia E Love; Elizabeth Head
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2014-12-08

5.  Cardiometabolic Risk and Body Composition in Youth With Down Syndrome.

Authors:  Sheela N Magge; Babette S Zemel; Mary E Pipan; Samuel S Gidding; Andrea Kelly
Journal:  Pediatrics       Date:  2019-07-17       Impact factor: 7.124

Review 6.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

7.  DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.

Authors:  Christophe Noll; Chris Planque; Clémentine Ripoll; Fayçal Guedj; Anna Diez; Véronique Ducros; Nicole Belin; Arnaud Duchon; Jean-Louis Paul; Anne Badel; Bénédicte de Freminville; Yann Grattau; Henri Bléhaut; Yann Herault; Nathalie Janel; Jean-Maurice Delabar
Journal:  PLoS One       Date:  2009-10-21       Impact factor: 3.240

8.  Cardiovascular Disease, Single Nucleotide Polymorphisms; and the Renin Angiotensin System: Is There a MicroRNA Connection?

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  Int J Hypertens       Date:  2010-08-04       Impact factor: 2.420

9.  Lipid profiles of children with Down syndrome compared with their siblings.

Authors:  Tahira Adelekan; Sheela Magge; Justine Shults; Virginia Stallings; Nicolas Stettler
Journal:  Pediatrics       Date:  2012-05-14       Impact factor: 7.124

10.  LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's disease.

Authors:  Jose F Abisambra; Tina Fiorelli; Jaya Padmanabhan; Peter Neame; Inge Wefes; Huntington Potter
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.